.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, individuals along with metastatic intestinal tumors that acquired biomarker-matched therapies based upon circulating cyst DNA profiling presented a more significant scientific perk than those receiving unequaled treatment.